Pharmacogenomic Dosing of Clopidogrel After Percutaneous Coronary Intervention
A 62-year-old man undergoes percutaneous coronary intervention (PCI) with drug-eluting stent placement for acute coronary syndrome. He is prescribed aspirin 81 mg daily and clopidogrel 75 mg daily after a 600 mg loading dose. He has a history of smoking and diabetes. The institution has pharmacogenomic testing available, and the pharmacist considers CYP2C19 genotype. The patient is concerned about stent thrombosis and asks about genetic testing.
1. Explain the role of CYP2C19 genotype in clopidogrel response and recommend an alternative antiplatelet if the patient is a poor metabolizer.
Read the worked answer
Clopidogrel is a prodrug requiring activation by CYP2C19. Loss-of-function alleles (e.g., *2, *3) reduce active metabolite formation, decreasing platelet inhibition and increasing risk of stent thrombosis and cardiovascular events. If genotyping shows poor metabolizer status (two loss-of-function alleles), guidelines recommend switching to prasugrel or ticagrelor, which are not dependent on CYP2C19 activation. Prasugrel 10 mg daily (or 5 mg if <60 kg or >75 years) or ticagrelor 90 mg twice daily are options. Consider bleeding risk: prasugrel contraindicated in prior stroke/TIA; ticagrelor may cause dyspnea. For intermediate metabolizers (one loss-of-function allele), consider alternative or continue clopidogrel with close monitoring. Do not double clopidogrel dose routinely. The pharmacist should recommend genotyping before starting clopidogrel in high-risk PCI patients if feasible.
2. How would you counsel the patient about genetic testing and the implications for his antiplatelet therapy?
Read the worked answer
Explain that genetic testing is a simple blood or saliva test that can identify how his body metabolizes clopidogrel. If he carries variants reducing enzyme activity, he may have a higher risk of stent clots, and an alternative drug (prasugrel or ticagrelor) may be safer and more effective. Discuss that testing results are confidential and guide therapy. Emphasize that he should not stop antiplatelet therapy without consulting his cardiologist, as this increases stent thrombosis risk. Address cost/insurance coverage. If testing is not available, consider empirical use of ticagrelor or prasugrel in high-risk patients, weighing bleeding risk. Document the discussion.